

29 January 2025

Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
Department of Health and Ageing
GPO Box 9848 Canberra ACT 2601

Dear PBAC Chair,

RE: Extension of PBS listing of Dupixent® (dupilumab) for patients aged less than 12 years

We are writing on behalf of the National Allergy Council and Allergy & Anaphylaxis Australia, in support of the request by Sanofi-Aventis Australia Pty Ltd for the Pharmaceutical Benefits Scheme (PBS) listing of Dupixent® (dupilumab) as follows:

To request the extension of two new forms to a General Schedule Authority Required listing for the treatment of severe atopic dermatitis in patients aged less than 12 years and a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of uncontrolled severe asthma in patients aged 6 to 11 years for Dupilumab (Dupixent®) Injection 200 mg in 1.14 mL single dose pre-filled pen and Injection 300 mg in 2 mL single dose pre-filled pen.

We support this request to ensure equitable access to Dupixent®, a medication which is effective in managing severe eczema and asthma, without the potential short and long term effects of alternative systemic therapies, thereby improving the health and well-being of children with significant atopic disease. Furthermore, patients under 12 years of age commonly suffer from these conditions and would not be able to access this medication without PBS subsidy.

Kind regards,

Ms Maria Said AM
CEO
Allergy & Anaphylaxis Australia

Dr Sandra Vale
CEO
National Allergy Council